Glen Laird - Concepedia

Author

Glen Laird

Novartis (United States)

Also Known As

G. H. Laird, G. Laird, Glen Laird

Publications

745

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)The University of Texas MD Anderson Cancer Center Peter MacCallum Cancer Centre Johannes Gutenberg University Mainz Tris Pharma (United States)

About

Glen Laird is an author at Novartis (United States) specializing in medicine, health sciences, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	163
2	Health Sciences	5	5	118
3	Public Health	1	1	45
4	Biostatistics	1	1	45
5	Counseling	1	1	11

Glen Laird

Publications

631

Citations

H-Index

Page 1

	Year	Citations
A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients with Refractory Hematologic Malignancies Francis J. Giles, Thomas Fischer, Jörge E. Cortes, Clinical Cancer Research	2006	314
Goodness‐of‐fit test for proportional subdistribution hazards model Bingqing Zhou, Jason P. Fine, Glen Laird Statistics in Medicine	2013	60
Phase IA/II Study of Oral Panobinostat (LBH589), a Novel Pan- Deacetylase Inhibitor (DACi) Demonstrating Efficacy in Patients with Advanced Hematologic Malignancies. Oliver G. Ottmann, Andrew Spencer, H. Miles Prince, Blood	2008	50
A Bayesian Case Study in Oncology Phase I Combination Dose-Finding Using Logistic Regression with Covariates Stuart Bailey, Beat Neuenschwander, Glen Laird, Journal of Biopharmaceutical Statistics Bayesian StatisticMtd PairPharmacotherapyOncologyBiostatistics	2009	45
Psychiatric Comorbidity and Not Completing Jail‐based Substance Abuse Treatment Thomas M. Brady, Christopher Krebs, Glen Laird American Journal on Addictions Substance UseMental HealthDrug TreatmentMental IllnessSubstance Use Disorders	2004	42
Cardiac monitoring in phase I trials of a novel histone deacetylase (HDAC) inhibitor LAQ824 in patients with advanced solid tumors and hematologic malignancies Eric K. Rowinsky, Johann S. de Bono, D. J. Deangelo, Journal of Clinical Oncology Cardiovascular PharmacologyPathologyPharmacotherapyOutlier EcgsCardiac Monitoring	2005	31
Phase II Trial of Oral Panobinostat (LBH589) in Patients with Refractory Cutaneous T-Cell Lymphoma (CTCL). Madeleine Duvic, Jürgen C. Becker, Stéphane Dalle, Blood	2008	28
Results of cardiac monitoring during phase I trials of a novel histone deacetylase (HDAC) inhibitor LBH589 in patients with advanced solid tumors and hematologic malignancies Thomas Fischer, Akash Patnaik, Kapil N. Bhalla, Journal of Clinical Oncology Inhibitor Lbh589Cardiovascular PharmacologyPharmacotherapyOutlier EcgsCardiac Monitoring	2005	24
Phase IA/II Study of Oral LBH589, a Novel Deacetylase Inhibitor (DACi), Administered on 2 Schedules, in Patients with Advanced Hematologic Malignancies. Andrew Spencer, Miles Prince, Daniel J. DeAngelo, Blood	2007	16
Jail-Based Substance User Treatment: An Analysis of Retention Christopher Krebs, Thomas M. Brady, Glen Laird Substance Use & Misuse CounselingSubstance AbuseSubstance UsePsychiatryAddiction Treatment	2003	11

Page 1